La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease

Identifieur interne : 000356 ( Pmc/Corpus ); précédent : 000355; suivant : 000357

Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease

Auteurs : Vanessa Brochard ; Béhazine Combadière ; Annick Prigent ; Yasmina Laouar ; Aline Perrin ; Virginie Beray-Berthat ; Olivia Bonduelle ; Daniel Alvarez-Fischer ; Jacques Callebert ; Jean-Marie Launay ; Charles Duyckaerts ; Richard A. Flavell ; Etienne C. Hirsch ; Stéphane Hunot

Source :

RBID : PMC:2613467

Abstract

Parkinson disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine-containing neurons. Mounting evidence suggests that dopaminergic cell death is influenced by the innate immune system. However, the pathogenic role of the adaptive immune system in PD remains enigmatic. Here we showed that CD8+ and CD4+ T cells but not B cells had invaded the brain in both postmortem human PD specimens and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD during the course of neuronal degeneration. We further demonstrated that MPTP-induced dopaminergic cell death was markedly attenuated in the absence of mature T lymphocytes in 2 different immunodeficient mouse strains (Rag1–/– and Tcrb–/– mice). Importantly, similar attenuation of MPTP-induced dopaminergic cell death was seen in mice lacking CD4 as well as in Rag1–/– mice reconstituted with FasL-deficient splenocytes. However, mice lacking CD8 and Rag1–/– mice reconstituted with IFN-γ–deficient splenocytes were not protected. These data indicate that T cell–mediated dopaminergic toxicity is almost exclusively arbitrated by CD4+ T cells and requires the expression of FasL but not IFNγ. Further, our data may provide a rationale for targeting the adaptive arm of the immune system as a therapeutic strategy in PD.


Url:
DOI: 10.1172/JCI36470
PubMed: 19104149
PubMed Central: 2613467

Links to Exploration step

PMC:2613467

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Infiltration of CD4
<sup>+</sup>
lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease </title>
<author>
<name sortKey="Brochard, Vanessa" sort="Brochard, Vanessa" uniqKey="Brochard V" first="Vanessa" last="Brochard">Vanessa Brochard</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Combadiere, Behazine" sort="Combadiere, Behazine" uniqKey="Combadiere B" first="Béhazine" last="Combadière">Béhazine Combadière</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM U543, Université Pierre et Marie Curie — Paris 06, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Prigent, Annick" sort="Prigent, Annick" uniqKey="Prigent A" first="Annick" last="Prigent">Annick Prigent</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Laouar, Yasmina" sort="Laouar, Yasmina" uniqKey="Laouar Y" first="Yasmina" last="Laouar">Yasmina Laouar</name>
<affiliation>
<nlm:aff id="JCI36470">Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Perrin, Aline" sort="Perrin, Aline" uniqKey="Perrin A" first="Aline" last="Perrin">Aline Perrin</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Beray Berthat, Virginie" sort="Beray Berthat, Virginie" uniqKey="Beray Berthat V" first="Virginie" last="Beray-Berthat">Virginie Beray-Berthat</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Bonduelle, Olivia" sort="Bonduelle, Olivia" uniqKey="Bonduelle O" first="Olivia" last="Bonduelle">Olivia Bonduelle</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM U543, Université Pierre et Marie Curie — Paris 06, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Alvarez Fischer, Daniel" sort="Alvarez Fischer, Daniel" uniqKey="Alvarez Fischer D" first="Daniel" last="Alvarez-Fischer">Daniel Alvarez-Fischer</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Callebert, Jacques" sort="Callebert, Jacques" uniqKey="Callebert J" first="Jacques" last="Callebert">Jacques Callebert</name>
<affiliation>
<nlm:aff id="JCI36470">CR Claude Bernard, IFR6, Service de Biochimie, Hôpital Lariboisière, Assistance Publique — Hôpitaux de Paris, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Launay, Jean Marie" sort="Launay, Jean Marie" uniqKey="Launay J" first="Jean-Marie" last="Launay">Jean-Marie Launay</name>
<affiliation>
<nlm:aff id="JCI36470">CR Claude Bernard, IFR6, Service de Biochimie, Hôpital Lariboisière, Assistance Publique — Hôpitaux de Paris, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Duyckaerts, Charles" sort="Duyckaerts, Charles" uniqKey="Duyckaerts C" first="Charles" last="Duyckaerts">Charles Duyckaerts</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Flavell, Richard A" sort="Flavell, Richard A" uniqKey="Flavell R" first="Richard A." last="Flavell">Richard A. Flavell</name>
<affiliation>
<nlm:aff id="JCI36470">Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C." last="Hirsch">Etienne C. Hirsch</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Hunot, Stephane" sort="Hunot, Stephane" uniqKey="Hunot S" first="Stéphane" last="Hunot">Stéphane Hunot</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">19104149</idno>
<idno type="pmc">2613467</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613467</idno>
<idno type="RBID">PMC:2613467</idno>
<idno type="doi">10.1172/JCI36470</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">000356</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000356</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Infiltration of CD4
<sup>+</sup>
lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease </title>
<author>
<name sortKey="Brochard, Vanessa" sort="Brochard, Vanessa" uniqKey="Brochard V" first="Vanessa" last="Brochard">Vanessa Brochard</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Combadiere, Behazine" sort="Combadiere, Behazine" uniqKey="Combadiere B" first="Béhazine" last="Combadière">Béhazine Combadière</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM U543, Université Pierre et Marie Curie — Paris 06, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Prigent, Annick" sort="Prigent, Annick" uniqKey="Prigent A" first="Annick" last="Prigent">Annick Prigent</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Laouar, Yasmina" sort="Laouar, Yasmina" uniqKey="Laouar Y" first="Yasmina" last="Laouar">Yasmina Laouar</name>
<affiliation>
<nlm:aff id="JCI36470">Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Perrin, Aline" sort="Perrin, Aline" uniqKey="Perrin A" first="Aline" last="Perrin">Aline Perrin</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Beray Berthat, Virginie" sort="Beray Berthat, Virginie" uniqKey="Beray Berthat V" first="Virginie" last="Beray-Berthat">Virginie Beray-Berthat</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Bonduelle, Olivia" sort="Bonduelle, Olivia" uniqKey="Bonduelle O" first="Olivia" last="Bonduelle">Olivia Bonduelle</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM U543, Université Pierre et Marie Curie — Paris 06, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Alvarez Fischer, Daniel" sort="Alvarez Fischer, Daniel" uniqKey="Alvarez Fischer D" first="Daniel" last="Alvarez-Fischer">Daniel Alvarez-Fischer</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Callebert, Jacques" sort="Callebert, Jacques" uniqKey="Callebert J" first="Jacques" last="Callebert">Jacques Callebert</name>
<affiliation>
<nlm:aff id="JCI36470">CR Claude Bernard, IFR6, Service de Biochimie, Hôpital Lariboisière, Assistance Publique — Hôpitaux de Paris, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Launay, Jean Marie" sort="Launay, Jean Marie" uniqKey="Launay J" first="Jean-Marie" last="Launay">Jean-Marie Launay</name>
<affiliation>
<nlm:aff id="JCI36470">CR Claude Bernard, IFR6, Service de Biochimie, Hôpital Lariboisière, Assistance Publique — Hôpitaux de Paris, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Duyckaerts, Charles" sort="Duyckaerts, Charles" uniqKey="Duyckaerts C" first="Charles" last="Duyckaerts">Charles Duyckaerts</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Flavell, Richard A" sort="Flavell, Richard A" uniqKey="Flavell R" first="Richard A." last="Flavell">Richard A. Flavell</name>
<affiliation>
<nlm:aff id="JCI36470">Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C." last="Hirsch">Etienne C. Hirsch</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Hunot, Stephane" sort="Hunot, Stephane" uniqKey="Hunot S" first="Stéphane" last="Hunot">Stéphane Hunot</name>
<affiliation>
<nlm:aff id="JCI36470">INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="JCI36470">Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.</nlm:aff>
</affiliation>
</author>
</analytic>
<series>
<title level="j">The Journal of Clinical Investigation</title>
<idno type="ISSN">0021-9738</idno>
<idno type="eISSN">1558-8238</idno>
<imprint>
<date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>Parkinson disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine-containing neurons. Mounting evidence suggests that dopaminergic cell death is influenced by the innate immune system. However, the pathogenic role of the adaptive immune system in PD remains enigmatic. Here we showed that CD8
<sup>+</sup>
and CD4
<sup>+</sup>
T cells but not B cells had invaded the brain in both postmortem human PD specimens and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD during the course of neuronal degeneration. We further demonstrated that MPTP-induced dopaminergic cell death was markedly attenuated in the absence of mature T lymphocytes in 2 different immunodeficient mouse strains (
<italic>Rag1
<sup>–/–</sup>
</italic>
and
<italic>Tcrb
<sup>–/–</sup>
</italic>
mice). Importantly, similar attenuation of MPTP-induced dopaminergic cell death was seen in mice lacking CD4 as well as in
<italic>Rag1
<sup>–/–</sup>
</italic>
mice reconstituted with FasL-deficient splenocytes. However, mice lacking CD8 and
<italic>Rag1
<sup>–/–</sup>
</italic>
mice reconstituted with IFN-γ–deficient splenocytes were not protected. These data indicate that T cell–mediated dopaminergic toxicity is almost exclusively arbitrated by CD4
<sup>+</sup>
T cells and requires the expression of FasL but not IFNγ. Further, our data may provide a rationale for targeting the adaptive arm of the immune system as a therapeutic strategy in PD. </p>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="publisher-id">J CLIN INVEST</journal-id>
<journal-title>The Journal of Clinical Investigation</journal-title>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">19104149</article-id>
<article-id pub-id-type="pmc">2613467</article-id>
<article-id pub-id-type="publisher-id">36470</article-id>
<article-id pub-id-type="doi">10.1172/JCI36470</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Infiltration of CD4
<sup>+</sup>
lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease </article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Brochard</surname>
<given-names>Vanessa</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">1</xref>
<xref ref-type="aff" rid="JCI36470">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Combadière</surname>
<given-names>Béhazine</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prigent</surname>
<given-names>Annick</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">1</xref>
<xref ref-type="aff" rid="JCI36470">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Laouar</surname>
<given-names>Yasmina</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perrin</surname>
<given-names>Aline</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">1</xref>
<xref ref-type="aff" rid="JCI36470">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beray-Berthat</surname>
<given-names>Virginie</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">1</xref>
<xref ref-type="aff" rid="JCI36470">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bonduelle</surname>
<given-names>Olivia</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alvarez-Fischer</surname>
<given-names>Daniel</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">1</xref>
<xref ref-type="aff" rid="JCI36470">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Callebert</surname>
<given-names>Jacques</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Launay</surname>
<given-names>Jean-Marie</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duyckaerts</surname>
<given-names>Charles</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">1</xref>
<xref ref-type="aff" rid="JCI36470">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flavell</surname>
<given-names>Richard A.</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">4</xref>
<xref ref-type="aff" rid="JCI36470">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hirsch</surname>
<given-names>Etienne C.</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">1</xref>
<xref ref-type="aff" rid="JCI36470">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hunot</surname>
<given-names>Stéphane</given-names>
</name>
<xref ref-type="aff" rid="JCI36470">1</xref>
<xref ref-type="aff" rid="JCI36470">2</xref>
</contrib>
</contrib-group>
<aff id="JCI36470">
<label>1</label>
INSERM, UMR S679, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France.
<label>2</label>
Université Pierre et Marie Curie — Paris 06, UMR S679, Paris, France.
<label>3</label>
INSERM U543, Université Pierre et Marie Curie — Paris 06, Paris, France.
<label>4</label>
Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
<label>5</label>
CR Claude Bernard, IFR6, Service de Biochimie, Hôpital Lariboisière, Assistance Publique — Hôpitaux de Paris, Paris, France.
<label>6</label>
Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Stéphane Hunot or Etienne C. Hirsch, INSERM UMR 679, Hôpital de la Salpêtrière, 47 Bd de l’Hôpital, 75013 Paris, France. Phone: 33-14-21-62-172; Fax: 33-14-42-43-658; E-mail:
<email>stephane.hunot@upmc.fr</email>
(S. Hunot). Phone: 33-14-21-62-202; Fax: 33-14-42-43-658; E-mail:
<email>etienne.hirsch@upmc.fr</email>
(E.C. Hirsch). </corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>12</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="ppub">
<day>5</day>
<month>1</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>5</day>
<month>1</month>
<year>2009</year>
</pub-date>
<pmc-comment> PMC Release delay is 0 months and 0 days and was based on the . </pmc-comment>
<volume>119</volume>
<issue>1</issue>
<fpage>182</fpage>
<lpage>192</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>6</month>
<year>2008</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>11</month>
<year>2008</year>
</date>
</history>
<copyright-statement>Copyright © 2009, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2009</copyright-year>
<abstract>
<p>Parkinson disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine-containing neurons. Mounting evidence suggests that dopaminergic cell death is influenced by the innate immune system. However, the pathogenic role of the adaptive immune system in PD remains enigmatic. Here we showed that CD8
<sup>+</sup>
and CD4
<sup>+</sup>
T cells but not B cells had invaded the brain in both postmortem human PD specimens and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD during the course of neuronal degeneration. We further demonstrated that MPTP-induced dopaminergic cell death was markedly attenuated in the absence of mature T lymphocytes in 2 different immunodeficient mouse strains (
<italic>Rag1
<sup>–/–</sup>
</italic>
and
<italic>Tcrb
<sup>–/–</sup>
</italic>
mice). Importantly, similar attenuation of MPTP-induced dopaminergic cell death was seen in mice lacking CD4 as well as in
<italic>Rag1
<sup>–/–</sup>
</italic>
mice reconstituted with FasL-deficient splenocytes. However, mice lacking CD8 and
<italic>Rag1
<sup>–/–</sup>
</italic>
mice reconstituted with IFN-γ–deficient splenocytes were not protected. These data indicate that T cell–mediated dopaminergic toxicity is almost exclusively arbitrated by CD4
<sup>+</sup>
T cells and requires the expression of FasL but not IFNγ. Further, our data may provide a rationale for targeting the adaptive arm of the immune system as a therapeutic strategy in PD. </p>
</abstract>
</article-meta>
</front>
<floats-wrap>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Lymphocyte infiltration in brains of patients of with PD.</title>
<p>(
<bold>A</bold>
) CD8 and (
<bold>B</bold>
) CD4 immunostaining with hematein counterstain on mesencephalic transverse sections from PD patients. CD8
<sup>+</sup>
or CD4
<sup>+</sup>
T cells (arrows) are found in close contact with blood vessels or have migrated deep into the brain parenchyma close to neuromelanin-containing DNs (arrowheads). Note that brain staining for CD79α and CD20 (B cells) and CD57 (NK cells) was not detected in either group of patients. All antibodies were previously tested on human tonsil tissue sections taken as a positive control, and all of them gave the expected cellular staining (Supplemental Figure 1). Scale bars: 250 μm (upper panel in
<bold>A</bold>
and upper-left panel in
<bold>B</bold>
); 30 μm (dashed boxes); 15 μm (upper-right panel in
<bold>B</bold>
). (
<bold>C</bold>
) Ultrastructural view of an infiltrated CD8
<sup>+</sup>
T cell in the SNpc from a parkinsonian patient. Parenchymal CD8
<sup>+</sup>
T cells display a small cytoplasmic volume, membrane-type CD8 staining (arrowheads), and a uropod-like cytoplasmic extension, usually involved in T cell motility (arrow). Per, pericyte; BM, basal membrane; e, endothelial cell; m, mitochondria; n, nucleus. Scale bar: 4 μm. (
<bold>D</bold>
) Density of infiltrated CD8
<sup>+</sup>
(left panel) and CD4
<sup>+</sup>
T cells (right panel) in the SNpc of parkinsonian patients (
<italic>n</italic>
= 14 and 9 for CD8 and CD4 staining, respectively) and age-matched control subjects (
<italic>n</italic>
= 4 and 7 for CD8 and CD4 staining, respectively). Bars represent the mean density. *
<italic>P <</italic>
0.05, **
<italic>P <</italic>
0.001 compared with controls (Student’s
<italic>t</italic>
test). </p>
</caption>
<graphic xlink:href="JCI0936470.f1"></graphic>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>MPTP-induced nigrostriatal pathway injury stimulates T cell brain infiltration in mouse.</title>
<p>(
<bold>A</bold>
) Schematic representation of the experimental approach (see Methods). The green circle within reconstituted mice refers to the lymphoid compartments replenished with GFP
<sup>+</sup>
cells. (
<bold>B</bold>
) GFP
<sup>+</sup>
T cell infiltration in the SNpc and (
<bold>C</bold>
) striatum following MPTP intoxication. Numerous GFP
<sup>+</sup>
T cells can be seen in the SNpc 2 days after MPTP but not saline exposure. GFP
<sup>+</sup>
T cells are also found in the striatum from intoxicated mice, though there are far fewer than in the SNpc. Scale bars: 300 μm (
<bold>B</bold>
); 100 μm (
<bold>C</bold>
); 10 μm (insets). (
<bold>D</bold>
) Immunofluorescent staining for TH, Glut1, CD8, or CD4. Note that infiltrated GFP
<sup>+</sup>
T cells are clustered within the SNpc in close proximity to TH
<sup>+</sup>
DNs. Transmigrated GFP
<sup>+</sup>
T cells are not found in the lumen of Glut1
<sup>+</sup>
blood vessels (arrows) and consist of both CD8
<sup>+</sup>
and CD4
<sup>+</sup>
T cell subsets. Scale bars: 20 μm. (
<bold>E</bold>
) T cell brain infiltration in MPTP-treated C57BL/6 inbred mice. CD3 immunostaining showing numerous T lymphocytes within the SNpc (dashed line) from MPTP-treated mice (left panel). Scale bar: 100 μm. Kinetic of nigral CD4
<sup>+</sup>
and CD8
<sup>+</sup>
T cell (insets) density after MPTP exposure (right panel). S, saline. Data points represent the mean ± SEM. *
<italic>P <</italic>
0.01 compared with saline- and MPTP-treated mice at day 4 after MPTP exposure;
<sup></sup>
<italic>P <</italic>
0.01 compared with saline-treated controls (Tukey post-hoc analysis). Scale bars: 50 μm. (
<bold>F</bold>
) Double immunofluorescence staining for PCNA and GFP and GFAP or Mac1. Note that PCNA
<sup>+</sup>
cells in the SNpc never colocalize with GFP
<sup>+</sup>
or GFAP
<sup>+</sup>
cells, whereas they superpose perfectly with Mac-1
<sup>+</sup>
macrophages/microglial cells (arrows). Scale bar: 50 μm. </p>
</caption>
<graphic xlink:href="JCI0936470.f2"></graphic>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Mechanism of lymphocyte entry into the brain.</title>
<p>(
<bold>A</bold>
) Immunofluorescent staining for serum albumin on brain sections (forebrain and hindbrain levels are shown) from mice sacrificed 6 hours after the last MPTP or saline injection. Patches of staining (arrows) are detected in various brain areas at 6 hours following MPTP exposure but not after saline treatment. The dashed line indicates the boundary between the striatal and cortical areas. CTX, cortex; STR, striatum; RMC, magnocellular part of the red nucleus; VTA, ventral tegmental area; SNC, substantia nigra compacta; SNR, substantia nigra reticulata; Aq, aqueduct of Sylvius; cp, cerebral peduncle. Scale bar: 300 μm. (
<bold>B</bold>
) Immunostaining for CD54/ICAM-1 (red) on mesencephalic sections from MPTP-intoxicated GFP
<sup>+</sup>
T cell–reconstituted
<italic>Rag
<sup>–/–</sup>
</italic>
mice. The expression pattern of CD54 overlaps with that of the GFP
<sup>+</sup>
T cell infiltrate within the SNpc (dashed line) (left panel). At higher magnification (right panel), CD54 expression is visible on GFP
<sup>+</sup>
T cells (arrows), blood vessels (asterisks), and branched glial cells (arrowheads). Scale bars: 300 μm (left panel); 10 μm (right panel). </p>
</caption>
<graphic xlink:href="JCI0936470.f3"></graphic>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>Mice deficient in CD4
<sup>+</sup>
T cells are more resistant to MPTP. </title>
<p>(
<bold>A</bold>
) Quantification of TH
<sup>+</sup>
DNs in the SNpc at day 7 after MPTP (4 × 18 mg/kg) or saline treatment in WT,
<italic>Tcrb
<sup>–/–</sup>
</italic>
,
<italic>Cd8a
<sup>–/–</sup>
</italic>
, and
<italic>Cd4
<sup>–/–</sup>
</italic>
mice. Bars represent the mean number of total nigral TH
<sup>+</sup>
DNs. Open symbols indicate saline-treated animals and filled symbols indicate MPTP-treated animals. Each symbol represents 1 individual animal. A significant protection against MPTP-induced DN cell loss is observed in
<italic>Tcrb
<sup>–/–</sup>
</italic>
and
<italic>Cd4
<sup>–/–</sup>
</italic>
mice but not in
<italic>Cd8a
<sup>–/–</sup>
</italic>
animals as compared with their WT littermates. *
<italic>P <</italic>
0.05 compared with MPTP-treated WT and
<italic>Cd8a
<sup>–/–</sup>
</italic>
mice;
<sup></sup>
<italic>P</italic>
= 0.956 compared with MPTP-treated WT littermates (Tukey post-hoc analysis). Nissl
<sup>+</sup>
cell counts confirmed that TH
<sup>+</sup>
cell loss was not a consequence of downregulated expression of TH (data not shown). (
<bold>B</bold>
) Representative photomicrographs of mesencephalic sections immunostained for TH with Nissl counterstain from saline- or MPTP-treated WT and lymphocytic deficient mice. Insets show Mac-1
<sup>+</sup>
microglial cells (arrows) in the SNpc from the same animals. Scale bar: 300 μm; 100 μm (insets). (
<bold>C</bold>
) Quantification of the total number of infiltrated CD4
<sup>+</sup>
and CD8
<sup>+</sup>
T cells in the SNpc from MPTP-treated WT and lymphocytic deficient mice. MPTP-treated
<italic>Cd8a
<sup>–/–</sup>
</italic>
mice display as many CD4
<sup>+</sup>
T cells as MPTP-treated WT littermates. **
<italic>P <</italic>
0.05 compared with saline-injected WT mice (Mann-Whitney
<italic>U</italic>
test).
<sup>††</sup>
<italic>P <</italic>
0.001 compared with MPTP-treated WT and
<italic>Cd8a
<sup>–/–</sup>
</italic>
mice;
<sup>#</sup>
<italic>P <</italic>
0.001 compared with MPTP-treated WT mice (Dunn test). ND, not detected. </p>
</caption>
<graphic xlink:href="JCI0936470.f4"></graphic>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>FasL, but not IFN-γ, is required for T cell–mediated DN toxicity in MPTP mouse.</title>
<p>(
<bold>A</bold>
) Quantification of TH
<sup>+</sup>
DNs in the SNpc at day 7 after MPTP (4 × 18 mg/kg) or saline treatment in WT and
<italic>Rag1
<sup>–/–</sup>
</italic>
mice reconstituted with spleen cells from either C57BL/6 inbred or
<italic>Ifng
<sup>–/–</sup>
</italic>
donors. All groups of animals are equally sensitive to MPTP-induced DN injury. *
<italic>P <</italic>
0.05 compared with their saline counterparts;
<sup></sup>
<italic>P <</italic>
0.05 compared with their saline counterparts but not different from MPTP-treated WT mice (Tukey post-hoc analysis). (
<bold>B</bold>
) Quantification of TH
<sup>+</sup>
DNs in the SNpc at day 7 after MPTP (4 × 18 mg/kg) or saline treatment in nonreconstituted
<italic>Rag1
<sup>–/–</sup>
</italic>
mice (non rec.
<italic>Rag1
<sup>–/–</sup>
</italic>
) and in
<italic>Rag1
<sup>–/–</sup>
</italic>
mice reconstituted with spleen cells from either C57BL/6 or
<italic>gld</italic>
donors (WT rec.
<italic>Rag1
<sup>–/–</sup>
</italic>
and
<italic>gld</italic>
rec.
<italic>Rag1
<sup>–/–</sup>
</italic>
, respectively). Nonreconstituted
<italic>Rag1
<sup>–/–</sup>
</italic>
mice and
<italic>gld</italic>
rec.
<italic>Rag1
<sup>–/–</sup>
</italic>
mice are partially protected against MPTP-induced DN loss as compared with WT rec.
<italic>Rag1
<sup>–/–</sup>
</italic>
animals. **
<italic>P <</italic>
0.01 compared with MPTP-intoxicated WT rec.
<italic>Rag1
<sup>–/–</sup>
</italic>
mice (Tukey post-hoc
<italic></italic>
analysis). (
<bold>A</bold>
and
<bold>B</bold>
) Open symbols indicate saline-treated animals and filled symbols indicate MPTP-treated animals. Each symbol represents 1 individual animal. Bars represent the mean number of total nigral TH
<sup>+</sup>
DNs. (
<bold>C</bold>
) Representative photomicrographs of mesencephalic sections immunostained for TH with Nissl counterstain from saline- or MPTP-treated WT rec.
<italic>Rag1
<sup>–/–</sup>
</italic>
and
<italic>gld</italic>
rec.
<italic>Rag1
<sup>–/–</sup>
</italic>
mice. Scale bar: 300 μm. </p>
</caption>
<graphic xlink:href="JCI0936470.f5"></graphic>
</fig>
<table-wrap id="T1" position="float">
<label>Table 1 </label>
<caption>
<p>Striatal monoamine levels (pM/mg tissue)</p>
</caption>
<graphic xlink:href="JCI0936470.t1"></graphic>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table 2 </label>
<caption>
<p>Striatal MPP
<sup>+</sup>
content after MPTP injection </p>
</caption>
<graphic xlink:href="JCI0936470.t2"></graphic>
</table-wrap>
</floats-wrap>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000356 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000356 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:2613467
   |texte=   Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease
            
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:19104149" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024